Esophageal Cancer, Esophagus Cancer
Conditions
Keywords
Esophageal Cancer, Esophagus Cancer, Memorial Sloan Kettering Cancer Center, 16-1631
Brief summary
Residual tumor at the proximal or distal margin after esophagectomy is a known prognostic factor for poor survival outcomes in patients with esophageal cancer; however, the significance of the circumferential resection margin (CRM) remains controversial. In this study, the investigators sought to evaluate the prognostic significance of the CRM in patients with esophageal cancer undergoing resection.
Interventions
PROCEDUREEsophagectomy
Esophagectomy
Sponsors
Memorial Sloan Kettering Cancer Center
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically confirmed esophageal adenocarcinoma (EAC) or esophageal squamous cell carcinoma (ESCC) undergoing esophagectomy * Pathologic staged T3 tumors (pT3)
Exclusion criteria
* Pathologic staged T0-2 (pT0-2) or T4 tumors (pT4) * Patients with histologic types other than EAC or ESCC, dysplasia or carcinoma in situ without tumor invasion, * Patients undergoing salvage esophagectomy * Evidence of distant metastatic disease * Patients with a positive proximal or distal margin
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| . Preoperative variables associated with overall survival and progression-free survival (measured from date of surgery) | Up to 2 years | Preoperative variables associated with overall survival and progression-free survival (measured from date of surgery) and the association between patient characteristics, neoadjuvant therapy, and postoperative morbidity. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival and progression-free survival (measured from date of surgery) | Up to 2 years | Postoperative outcomes stratified by the type of esophageal cancer surgery performed. |
| Postoperative outcomes stratified by the time between neoadjuvant therapy and surgery (i.e., delayed or immediate). | Up to 2 years | — |
| Survival outcomes stratified by treatment modality (i.e., definitive chemoradiation therapy or trimodality treatment). | Up to 2 years | — |
| Survival outcomes stratified by use of adjuvant therapy (i.e., adjuvant therapy or no adjuvant therapy). | Up to 2 years | — |
Countries
United States
Contacts
CONTACTDaniela Molena, MD
CONTACTJames Isbell, MD
PRINCIPAL_INVESTIGATORDaniela Molena, MD
Memorial Sloan Kettering Cancer Center
Outcome results
None listed